Andrew Gallagher

About
Latest Posts

Andrew Gallagher is chief operating officer at Phynova, a British life science company that develops and sells medically licensed drugs, functional ingredients and cosmeceuticals derived from active compounds found in plants.

Latest posts by Andrew Gallagher (see all)

Licensing traditional Chinese medicines - 15th September 2016

Licensing traditional Chinese medicines

Coronavirus, COVID-19 Update
Saliva based rapid test for COVID-19 antigen
A saliva based test for COVID-19 providing results directly to patients in minutes is being developed as a result of a new collaboration between Luas Diagnostics and the University of …
Coronavirus, COVID-19 Update, Heart & Lung, NHS
Referrals of urgent care lung conditions drop …
An average of 3,399 patients per week missed out on urgent and routine referrals during lockdown, according to the Taskforce for Lung Health. New analysis by the Taskforce for Lung …
Global Reach, Infection/Disease, Innovation, Pharmacy/Drugs
HIV treatment targets in sight
Ambitious annual target on HIV treatment could be achieved for equivalent of just one month of global spend on HIV drugs The Make Medicines Affordable campaign is calling for a …
Cancer, Coronavirus, COVID-19 Update
Cancer backlog: Action Radiotherapy response
Action Radiotherapy calls for an urgent resolution to the cancer backlog caused by the Covid-19 pandemic. “A dramatic intervention from Government and the NHS is needed to prevent thousands of …
Cancer, Infection/Disease, Innovation
CAR-T cell therapy
CAR-T cell therapy is a new and revolutionary weapon against cancer: T cells are isolated from the patient’s blood for genetic modification and then infused back into the patient to …

The Royal Society of Medicine blogs

View all posts from The RSM »

LATEST: RSM COVID-19 Series: Impact on older population